Ethical Justifications for Access to Unapproved Medical Interventions: An Argument for (Limited) Patient Obligations

American Journal of Bioethics

Volumn 14, Issue 11, 2014, Pages 3-15

  Walker, Mary Jean ^a   Rogers, Wendy A ^a   Entwistle, Vikki ^b  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

end of life issues; experimental therapies; health care delivery; patient rights; regulatory issues; research ethics; special access

Indexed keywords

COMPASSIONATE USE; CONFLICT; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; HUMAN; INFORMATION PROCESSING; KNOWLEDGE; MORALITY; PATIENT; RESEARCH ETHICS; SOCIAL PSYCHOLOGY;

COMPASSIONATE USE TRIALS; DATA COLLECTION; DISSENT AND DISPUTES; ETHICS, RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; KNOWLEDGE; MORAL OBLIGATIONS; PATIENTS; SOCIAL VALUES; THERAPIES, INVESTIGATIONAL;

EID: 84908025754     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2014.957416     Document Type: Article

References (65)

1. Abigail Alliance for Better Access to Developmental Drugs and the Washington Legal Foundation. 2003. Citizen Petition of the Abigail Alliance and the Washington Legal Foundation to the Food and Drug Administration, U.S. Dept. of Health and Human Services. Available at: http://www.fda.gov/ohrms/dockets/dailys/03/Jun03/061703/03p-0274-cp00001-01-vol1.pdf (accessed May 25, 2013).
2. Agence Francaise de securite sanitaire des produit de santé. 2007. Notice to applicants for Temporary Authorisation for Use (ATU). Paris, France: AFSSAPS.
3. American Society of Clinical Oncology with the Association of American Medical Colleges and the National Coalition for Cancer Survivorship. 2007. Amicus brief in the United States Court of Appeals for the District Court of Columbia, Case no. 04-5350.
4. Appelbaum, P. S., L. H. Roth, and C. Lidz. 1982. The therapeutic misconception: Informed consent in psychiatric research. International Journal of Law and Psychiatry 5: 319–329.
5. Atkinson, S., A. Blanc, D. Lebel, J.-F. Bussieres, B. Bailey, and A. Berard. 2007. Risk of drug interactions among children accessing drugs through Health Canada's Special Access Program. Canadian Journal of Hospital and Pharmacy 60: 114–120.
6. Barnabe, C., S. G. Barr, and L. Martin. 2012. Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure. Clinical Rheumatology 31: 211–217.
7. Bates, A. K. 2008. Implementing a pre-launch named patient programme: Evidence of increased market share. Journal of Medical Marketing 8(4): 319–324.
8. Beauchamp, T. L., and J. F. Childress. 2013. Principles of biomedical ethics seventh edition. New York, NY: Oxford University Press.
9. Bedlack, R. S. 2011. Compassionate use of stem cells for ALS: Popovers and hot air. Amytrophic Lateral Sclerosis 12: 313–314.
10. Bender, S., L. Flicker, and R. Rhodes. 2007. Access for the terminally ill to experimental medical innovations: A three-pronged threat. American Journal of Bioethics 7(10): 3–6.
11. Beran, R. G., and K. Sheehan. 1996. An appraisal of the clinical use of lamotrigine under the special access scheme. Journal of Clinical Neuroscience 3(3): 239–242.
12. Bristol, N. 2007. Should terminally ill patients have access to phase I drugs? Lancet 369: 815–816.
13. Caplan, A. 2007. Is it sound public policy to let the terminally ill access experimental medical innovations? American Journal of Bioethics 7(6): 1–3.
14. Carpenter, D., A. S. Kesselheim, and S. Joffe. 2011. Reputation and precedent in the Bevacizumab decision. New England Journal of Medicine 365: e3.
15. Chahal, M. 2010. Off-trial access to experimental cancer agents for the terminally ill: Balancing the needs of individuals and society. Journal of Medical Ethics 36: 367–370.
16. Cholst, I. N. 2013. Oocyte donation and the therapeutic misconception. Fertility and Sterility 99(6): 1561–1562.
17. Davis, M. 2006. Should experimental therapy be made available off-study for terminally ill patients? Lancet Oncology 7: 531–533.
18. DiMasi, J. A., R. W. Hansen, and H. Grabowski. 2003. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22: 151–185.
19. Dresser, R. 2006. Investigational drugs and the constitution. Hastings Centre Report November–December: 9–10.
20. Edwards, S. J. L. 2006. Restricted treatments, inducements, and research participation. Bioethics 20(2): 77–91.
21. Edwards, S. J. L. 2013. Ethics of clinical science in a public health emergency: Drug discovery at the bedside. American Journal of Bioethics 13(9): 3–14.
22. Epstein, R. M., and V. Entwistle. 2013. Capacity and shared decision-making in serious illness. In Palliative care and ethics: common ground and cutting edges, ed. T. E. Quill and F. G. Miller, 162–185. Oxford, UK: Oxford University Press.
23. European Community. 2001. European Community Directive 2001.83.EC. Available at: http://www.edctp.org/fileadmin/documents/ethics/DIRECTIVE_200183EC_OF_THE_EUROPEAN_ PARLIAMENT.pdf (accessed March 1, 2013).
24. European Community. 2004. European Community Regulation (EC) No 726/2004. Available at: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF (accessed March 1, 2013).
25. Evans, S., B. Loff, and P. Cameron. 2013. Clinical registries: The urgent need to address ethical hurdles. Medical Journal of Australia 198(3): 134–135.
26. Faden, R., N. Kass, S. N. Goodman, P. Pronovost, S. Tunis, and T. Beauchamp. 2013. An ethics framework for a learning healthcare system: A departure from traditional research ethics and clinical ethics. In Special report: Ethical oversight of learning healthcare systems. Hastings Centre Report January–February: S16–S27.
27. Falit, B. P., and C. P. Gross. 2008. Access to experimental drugs for terminally ill patients. Journal of the American Medical Association 300(23): 2793–2795.
28. Food and Drug Administration. 2009. Expanded access to investigational drugs for treatment use (Final rule). Federal Register 74(155): 40900–40945.
29. Food and Drug Administration. 2010. FDA approves left ventricular assist system for severe heart failure patients. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm198172.htm (accessed June 29, 201)3.
30. Food and Drug Administration. 2013. About FDA: What we do: History. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/default.htm (accessed May 13, 2013).
31. Ghinea, N., W. L. Lipworth, I. H Kerridge, and R. O. Day. 2012. No evidence or no alternative? Taking responsibility for off-label prescribing. Internal Medicine Journal 42(3): 247–251.
32. Hamilton, E., G. Lyman, and J. Peppercorn. 2010. Availability of experimental therapy outside oncology randomized clinical trials in the United States. Journal of Clinical Oncology 28(34): 5067–5073.
33. Harris, J. 2005. Scientific research is a moral duty. Journal of Medical Ethics 31(4): 242–248.
34. Health Canada. 2007. The medical devices special access programme. Ottawa, Canada: Therapeutic Products Directorate.
35. Health Canada. 2008. Guidance document for industry and practitioners: Special access programme for drugs. Ottawa, Canada: Minister of Public Works and Government Services.
36. Hofmann, B. 2002. Is there a technological imperative in healthcare? International Journal of Technology Assessment in Health Care 18(3): 675–689.
37. Institute of Medicine. 1991. Expanding access to investigational therapies for HIV infection and AIDS: Roundtable for the development of drugs and vaccines against AIDS. Washington, DC: National Academy of Sciences.
38. Isbister, J., L. Phillips, S. Dunkley, G. Jankelowitz, J. McNeil, and P. Cameron. 2008. Recombinant activated factor VII in critical bleeding: Experience from the Australian and New Zealand Haemostasis Register. Internal Medicine Journal 38: 156–165.
39. Jacobsen, P. D., and W. E. Parmet. 2007. A new era of unapproved drugs: The case of Abigail Allliance v Von Eschenbach. Journal of the American Medical Association 297(2): 205–208.
40. Kass, N., R. R. Faden, S. N. Goodman, P. Pronovost, S. Tunis, and T. L Beauchamp. 2013. The research–treatment distinction: A problematic approach for determining which activities should have ethical oversight. In Special report: Ethical oversight of learning healthcare systems. Hastings Centre Report January–February 2013: S4–S15.
41. Kelly, J. S. 2008. Experimental medicines in multiple sclerosis and compassionate use. Journal of the Royal College of Physicians Edinburgh 39: 35–37.
42. Largent, E. A., S. Joffe, and F. G Miller. 2011. Can research and care be ethically integrated? Hastings Centre Report July–August: 37–46.
43. Largent, E. A., F. G. Miller, and S. D. Pearson. 2009. Going off-label without venturing offcourse: Evidence and ethics in off-label prescribing. Archives of Internal Medicine 169(19): 1745–1747.
44. Leonard, E. W. 2009. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public's health. Journal of Law, Medicine and Ethics 37(2): 269–279.
45. Lundh, A., S. Sismondo, J. Lexchin, O. A. Busuioc, and L. Bero. 2012. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 12: MR000033.
46. Munthe, C. 2013. Precautionary principle. In International encyclopedia of ethics, ed. H. LaFollette, 4031–4039. Chichester, UK: Wiley-Blackwell.
47. Myerson, D. 2013. Innovative surgery and the precautionary principle. Journal of Medicine and Philosophy 38(6): 605–624.
48. National Prescribing Centre. 2011. Prescribing specials: Five guiding principles for prescribers. Liverpool, UK: National Institute for Health and Clinical Excellence.
49. Rago, L., and B. Santoso. 2008. Drug regulation: History, present and future. In Drug benefits and risks: International textbook of clinical pharmacology, ed. C. J. van Boxtel, B. Santoso, and I. R. Edwards, 65–77. Lansdale, PA: IOS Press.
50. Robertson, J. A. 2006. Controversial medical treatment and the right to health care. Hastings Centre Report 36(6): 15–20.
51. Ross, E. 2009. Unapproved drug use: Compassionate or cause for concern? The Lancet Neurology 8(2): 136–137.
52. Royal Australasian College of Physicians. 2013. The use of sustained release formulations of naltrexone in opioid dependence: Position statement. Sydney, Australia: RACP.
53. Schaefer, G. O., E. J. Emanuel, and A. Wertheimer. 2009. The obligation to participate in medical research. Journal of the American Medical Association 302(1): 67–72.
54. Schuklenk, U., and C. Lowry. 2009. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: Reviewing the ethical arguments. British Medical Bulletin 89: 7–22.
55. Shorr, A. F. 1992. AIDS and the FDA: An ethical case for limiting patient access to new medical therapies. IRB: Ethics and Human Research 14(4): 1–5.
56. Supreme Court of United States. 1979. Case 78-605, United States v. Rutherford. 442 U.S. 544 (1979).
57. Therapeutic Goods Administration. 2004. Access to unapproved therapeutic goods: Authorised prescribers. Canberra, Australia: TGA.
58. Therapeutic Goods Administration. 2009. Access to unapproved therapeutic goods via the Special Access Scheme. Canberra, Australia: TGA.
59. Therapeutic Goods Administration. 2012. Metal-on-metal hip replacement implants: Information for general practitioners, orthopaedic surgeons and other health professionals. Available at: http://www.tga.gov.au/hp/information-devices-mom-hipimplants.htm (accessed April 13, 2013).
60. U.S. Court of Appeals. 2007. Case 04-5350, Abigail Alliance for Better Access to Developmental Drugs et al. v. von Eschenbach et al. En banc reply brief of appellants.
61. Whitfield, K., K.-H. Huemer, D. Winter, 2010. Compassionate use of interventions: Results of a European Clinical Infrastructures Network (ECRIN) survey of ten European countries. Trials 11(104). doi: 10.1186/17456215-11-104
62. Wicks, P., T. Vaughan, M. Massagli, and J. Heywood. 2011. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Computational Biology 29(5): 411–414.
63. Widdows, H., and S. Cordell. 2011. Why communities and their goods matter: Illustrated with the example of biobanks. Public Health Ethics 4(1): 14–25.
64. Wipke-Tevis, D. D. 2001. What is research? Journal of Vascular Nursing 19(2): 63–64.
65. Young, P. 2009. Expanded access to INDs. Community Oncology 6(10): 478.